NCT05759195已完成不适用
Tumor Biomolecular Analysis for Defining Predictive Factors for Response to Regorafenib in Recurrent Glioblastoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS2 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2021年1月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 53
- 试验地点
- 2
- 主要终点
- Overall survival
研究概览
简要总结
The study envisages NGS analysis on tumor tissue from patients treated with regorafenib for recurrent glioblastoma as per standard care, with the aim to identify predictive biomarkers for response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •recurrent glioblastoma after surgery and chemoradiation with temozolomide;
- •indication to treatment with regorafenib per standard of care;
- •written informed consent.
排除标准
- 未提供
结局指标
主要结局
Overall survival
时间窗: through study completion, an average of 3 years
Interval between tumor diagnosis and death or end of follow-up
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal CancerMetastatic Colorectal CancerNCT01996969Seoul National University Hospital117
已完成
不适用
Predicting Disease Progression and/or Recurrence in CancerPatient Reported Outcome MeasuresBiliary Tract CancerMetastatic CancerDisease ProgressionSurvival AnalysisColorectal CancerEsophageal CancerPancreatic CancerNCT04776837Massachusetts General Hospital159
Unknown
不适用
Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective StudyOvarian CancerNCT02719041Hillel Yaffe Medical Center40
Unknown
不适用
Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian CancerOvarian CancerNCT02711865Hillel Yaffe Medical Center20
招募中
2 期
Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)Meningioma, MalignantNCT06275919Istituto Oncologico Veneto IRCCS104